Adamis Pharmaceuticals Resubmits ZIMHI New Drug Application to FDA for the Treatment of Opioid Overdose
17 mai 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 17, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals Schedules First Quarter 2021 Financial Results Conference Call and Business Update
12 mai 2021 07h30 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, May 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory disease,...
Adamis Pharmaceuticals Announces 2020 Financial Results and Business Update
15 avr. 2021 16h39 HE
|
Adamis Pharmaceuticals Corporation
Phase 2/3 clinical trial for Tempol for the prevention of hospitalizations in patients with COVID-19 expected to initiate in the second quarter of 2021 Management to host webcast/conference call...
Adamis Pharmaceuticals Schedules Fourth Quarter and Full Year 2020 Financial Results Conference Call and Business Update
13 avr. 2021 16h03 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, April 13, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP), a biopharmaceutical company developing and commercializing specialty products for respiratory...
Adamis Pharmaceuticals Provides an Update on ZIMHI™
12 avr. 2021 07h00 HE
|
Adamis Pharmaceuticals Corporation
SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today provided an update on the status of the company’s New Drug Application (NDA) relating to its...